Clinical utility of circulating tumor DNA in patients with advanced KRAS G12C-mutated NSCLC treated with sotorasib

被引：0
|
作者：
Ernst, Sophie M.
van Marion, Ronald
Atmodimedjo, Peggy N.
de Jonge, Evert
Mathijssen, Ron H.
Paats, Marthe S.
de Bruijn, Peter
van Schaik, Ron H. N.
Dubbink, Hendrikus J.
Dingemans, Anne-Marie C.
机构：
来源：
CANCER RESEARCH | 2023年 / 83卷 / 07期
关键词：
D O I：
10.1158/1538-7445.AM2023-2137
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
2137
引用
收藏
页数：3
相关论文
共 50 条
  • [1] Comment on "Clinical Utility of Circulating Tumor DNA in Patients With Advanced KRAS(G12C)-Mutated NSCLC Treated With Sotorasib"
    Jiang, Yanfang
    Zhang, Lei
    JOURNAL OF THORACIC ONCOLOGY, 2024, 19 (09) : e43 - e43
  • [2] A Response to the Letter to the Editor: Comment on "Clinical Utility of Circulating Tumor DNA in Patients With Advanced KRAS(G12C)-Mutated NSCLC Treated With Sotorasib"
    Ernst, Sophie M.
    von der Thusen, Jan H.
    Dubbink, Hendrikus J.
    Dingemans, Anne-Marie C.
    JOURNAL OF THORACIC ONCOLOGY, 2024, 19 (09)
  • [3] Clinical Utility of Circulating Tumor DNA in Patients With Advanced KRASG12C-Mutated NSCLC Treated With Sotorasib
    Ernst, Sophie M.
    van Marion, Ronald
    Atmodimedjo, Peggy N.
    de Jonge, Evert
    Mathijssen, Ron H. J.
    Paats, Marthe S.
    de Bruijn, Peter
    Koolen, Stijn L.
    von der Thuesen, Jan H.
    Aerts, Joachim G. J. V.
    Schaik, Ron H. N. van
    Dubbink, Hendrikus J.
    Dingemans, Anne-Marie C.
    JOURNAL OF THORACIC ONCOLOGY, 2024, 19 (07) : 995 - 1006
  • [4] Assessing the safety profile of sotorasib in KRAS G12C-mutated advanced NSCLC
    Reactions Weekly, 2025, 2045 (1) : 6 - 6
  • [5] Impact of Sotorasib and Adagrasib in KRAS G12C-Mutated NSCLC
    Patel, Sandip P.
    ONCOLOGY-NEW YORK, 2023, 37 (12): : 479 - 479
  • [6] Letter Regarding "Clinical Utility of Circulating Tumor DNA in Patients With Advanced KRASG12C-Mutated NSCLC Treated With Sotorasib"
    Ernst, Sophie M.
    von der Thusen, Jan H.
    Dubbink, Hendrikus J.
    Dingemans, Anne-Marie C.
    JOURNAL OF THORACIC ONCOLOGY, 2024, 19 (08) : e29 - e30
  • [7] Sotorasib (960 mg or 240 mg) once daily in patients with previously treated KRAS G12C-mutated advanced NSCLC
    Hochmair, Maximilian J.
    Vermaelen, Karim
    Mountzios, Giannis
    Carcereny, Enric
    Dooms, Christophe
    Lee, Se-Hoon
    Morocz, Eva
    Kato, Terufumi
    Ciuleanu, Tudor-Eliade
    Dy, Grace K.
    Parente, Barbara
    O'Byrne, Kenneth J.
    Chu, Quincy S.
    De Castro Junior, Gilberto
    Girard, Nicolas
    Snyder, Wendy
    Tran, Qui
    Kormany, William
    Houk, Brett
    Mehta, Bhakti
    Curioni-Fontecedro, Alessandra
    EUROPEAN JOURNAL OF CANCER, 2024, 208
  • [8] FDA Approval Summary: Sotorasib for KRAS G12C-Mutated Metastatic NSCLC
    Nakajima, Erica C.
    Drezner, Nicole
    Li, Xiaoxue
    Mishra-Kalyani, Pallavi S.
    Liu, Yajun
    Zhao, Hong
    Bi, Youwei
    Liu, Jiang
    Rahman, Atiqur
    Wearne, Emily
    Ojofeitimi, Idara
    Hotaki, Lauren Tesh
    Spillman, Dianne
    Pazdur, Richard
    Beaver, Julia A.
    Singh, Harpreet
    CLINICAL CANCER RESEARCH, 2022, 28 (08) : 1482 - 1486
  • [9] CodeBreaK 101: Safety and Efficacy of Sotorasib with Carboplatin and Pemetrexed in KRAS G12C-Mutated Advanced NSCLC
    Clarke, J. M.
    Felip, E.
    Li, B. T.
    Ruffinelli, J. C.
    Garrido, P.
    Zugazagoitia, J.
    Goldberg, S. B.
    Ramalingam, S. S.
    Victoria, I.
    Puri, S.
    Gandara, D. R.
    Varrieur, T.
    Edmonds, S.
    Palmer, K.
    Snyder, W.
    Govindan, R.
    Rybkin, I.
    JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (11) : S118 - S119
  • [10] Cost-Effectiveness Analysis of Sotorasib vs. Adagrasib in KRAS G12c-Mutated Previously Treated NSCLC
    Karim, N.
    Waterhouse, D.
    Jones, S.
    Stollenwerk, B.
    JOURNAL OF THORACIC ONCOLOGY, 2024, 19 (10) : S719 - S720
12345